KRAS and gastric cardia adenocarcinoma: Tajima et al (2007) compared the incidence of KRAS mutations in gastric cardia adenocarcinomas and distal stomach cancers and reported a 7% positive mutation rate in both groups. Although few trials have looked specifically at GEJ tumours, the 8% rate of KRAS mutation in this trial is consistent with reports in oesophageal and gastric cancers (Arber et al, 2000; Lord et al, 2000).